Persaud Sham, Chesser Anthony, Pereira Ryan, Ross Adrianne
West Penn Hospital Foot and Ankle Institute, Pittsburgh, Pennsylvania (SP, AC).
Anastasia Medical Group, St. Augustine, Florida (RP).
Foot Ankle Spec. 2017 Dec;10(6):560-566. doi: 10.1177/1938640017729496. Epub 2017 Sep 5.
The sural flap procedure is a versatile technique that can be used to cover many types of defects about the lower extremity. The management of soft tissue defects of the lower extremity with underlying osteomyelitis is difficult. The goal for any of these patients is to create a biomechanically stable foot for weight-bearing purposes with no continued infection. Data were gathered using multiple databases from the years 2000 to 2016. Data were compiled looking at the number of subjects, age, comorbidities, number of complications, number of failures, and average flap size of complications/failures. A total of 110 patients were gathered using 5 separate articles. Twenty-two of the 110 patients had short-term complications. Flap failure was seen in 9/110 patients. A significant difference was noticed in flap size between flap failure and complication groups and nonfailure groups. The average flap size of patients who had some form of complication or failure was 51.87 cm in size. The average graft size for patients without complications during their recovery was 36.54 cm. Within our study, the failure rate of 8.9% and complication rate of 13.7% are consistent with previous reports on sural perforator flaps. Last, with regard to the effect of flap size, there were significant differences between patients with a successful outcome and those who experienced complications or failures.
Therapeutic, Level III: Systematic review.
腓肠肌皮瓣手术是一种多功能技术，可用于覆盖下肢多种类型的缺损。处理伴有潜在骨髓炎的下肢软组织缺损很困难。所有这些患者的目标都是创建一个生物力学稳定的足部用于负重，且无持续感染。使用2000年至2016年的多个数据库收集数据。对受试者数量、年龄、合并症、并发症数量、失败数量以及并发症/失败的皮瓣平均大小进行汇总分析。通过5篇独立文章共收集了110例患者。110例患者中有22例出现短期并发症。110例患者中有9例皮瓣失败。皮瓣失败组与并发症组和非失败组之间在皮瓣大小上存在显著差异。出现某种形式并发症或失败的患者皮瓣平均大小为51.87平方厘米。恢复过程中无并发症患者的移植皮瓣平均大小为36.54平方厘米。在我们的研究中，8.9%的失败率和13.7%的并发症率与先前关于腓肠肌穿支皮瓣的报告一致。最后，关于皮瓣大小的影响，成功组与出现并发症或失败的患者之间存在显著差异。
治疗性，三级：系统评价。
